Decipher Labs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE643N01012
  • NSEID:
  • BSEID: 524752
INR
6.15
0.34 (5.85%)
BSENSE

Mar 05

BSE+NSE Vol: 8.45 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

8.45 k (-54.61%) Volume

Shareholding (Dec 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

16.43%

Who are the top shareholders of the Decipher Labs?

06-Jun-2025

The top shareholders of Decipher Labs include Ajjarapu Janakiram with 16.43% and Seshu Srinivas Akula with 3.8%. Individual investors collectively own 80.75% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Decipher Labs include Ajjarapu Janakiram, who holds the largest stake at 16.43%. The highest public shareholder is Seshu Srinivas Akula, with a holding of 3.8%. Additionally, individual investors collectively own a significant portion of the company, accounting for 80.75% of the shares. There are no institutional holdings or pledged promoter holdings reported.

View full answer

Has Decipher Labs declared dividend?

06-Jun-2025

No Dividend History Available

Who are the peers of the Decipher Labs?

03-Jun-2025

Decipher Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. While Sun Pharma and Cipla show excellent management and growth, Decipher Labs has below-average growth and capital structure, with a 1-year return of -37.22%.

Peers: The peers of Decipher Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Span Divergent, Unjha Formul., Checkpoint Trend, Vivanza Biosci., and Cian Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Decipher Labs and Unjha Formul. Below Average management risk is noted for Checkpoint Trend, Vivanza Biosci., and Cian Healthcare. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Decipher Labs, Unjha Formul., Checkpoint Trend, Vivanza Biosci., and Cian Healthcare. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Below Average capital structure is noted for Decipher Labs, and Average capital structure is observed at Unjha Formul. Good capital structure is seen at Torrent Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Cian Healthcare has the lowest at -82.59%. Decipher Labs' 1-year return is -37.22%, which is significantly lower than the highest return and higher than the lowest. Additionally, the six-month return is negative for Decipher Labs, Span Divergent, Unjha Formul., and Vivanza Biosci.

View full answer

Is Decipher Labs overvalued or undervalued?

09-Jun-2025

As of June 2, 2025, Decipher Labs is considered overvalued with a risky valuation grade, reflected by a negative PE ratio of -2.22, an EV to EBITDA of -1.20, and a year-to-date stock return of -24.62%, significantly underperforming its peers and the Sensex.

As of 2 June 2025, Decipher Labs has moved from an attractive to a risky valuation grade. The company is currently considered overvalued based on its financial metrics, with a PE ratio of -2.22, an EV to EBITDA of -1.20, and a ROCE of -38.00%. These figures indicate significant financial distress and lack of profitability, which is further underscored by a negative PEG ratio of 0.00.<BR><BR>In comparison to its peers, Decipher Labs stands out negatively; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE ratio of 22.99 and an EV to EBITDA of 15.93. The stark contrast in these ratios highlights Decipher Labs' struggles within the pharmaceuticals and biotechnology sector. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -24.62% compared to the Sensex's 5.66%, reinforcing the notion that Decipher Labs is overvalued at its current price of 11.27.

View full answer

What is the technical trend for Decipher Labs?

09-Jun-2025

As of June 4, 2025, Decipher Labs is in a bearish trend with moderate strength, driven by bearish daily moving averages and Bollinger Bands, despite some mildly bullish MACD signals.

As of 4 June 2025, the technical trend for Decipher Labs has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the daily moving averages, which are bearish, and the weekly and monthly Bollinger Bands also indicating a bearish trend. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall sentiment is dampened by the bearish moving averages and the Dow Theory, which is mildly bearish on both weekly and monthly scales. The stock's performance has significantly lagged behind the Sensex over various time frames, further supporting the bearish outlook.

View full answer

Who are in the management team of Decipher Labs?

16-Jul-2025

As of March 2022, the management team of Decipher Labs includes Sushant Mohan Lal (Executive Director), G Venkateswara Rao (Independent Director), and Megha Agarwal (Company Secretary and Compliance Officer).

As of March 2022, the management team of Decipher Labs includes Sushant Mohan Lal, who serves as the Executive Director, G Venkateswara Rao, who is an Independent Director, and Megha Agarwal, who holds the position of Company Secretary and Compliance Officer.

View full answer

What does Decipher Labs do?

17-Jul-2025

Decipher Labs Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 35 Cr and a net loss of 41 Cr for the quarter ending March 2025. The company has a market cap of INR 12 Cr and is based in Hyderabad, India.

Overview:<BR>Decipher Labs Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Decipher Labs Ltd was incorporated as a Private Limited Company in September 1986 and transitioned to a Public Limited Company in June 1992. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 35 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -41 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 12 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.11 <BR>Return on Equity: -22.22% <BR>Price to Book: 0.52<BR><BR>Contact Details:<BR>Address: 4th Flr Plot-94 Sagar Society, Banjara Hills Road No 2 Hyderabad Telangana : 500034 <BR>Email: info@combatdrugs.in <BR>Website: http://www.combatdrugs.in

View full answer

How big is Decipher Labs?

24-Jul-2025

As of 24th July, Decipher Labs Ltd has a market capitalization of 11.00 Cr and reported net sales of 22.61 Cr with a net loss of 5.08 Cr over the latest four quarters. Shareholder's funds were 21.86 Cr, and total assets were 33.08 Cr as of March 2024.

As of 24th July, Decipher Labs Ltd has a market capitalization of 11.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Decipher Labs reported net sales of 22.61 Cr. However, the company experienced a net loss of 5.08 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, where the shareholder's funds amounted to 21.86 Cr, and total assets were reported at 33.08 Cr.

View full answer

How has been the historical performance of Decipher Labs?

14-Nov-2025

Decipher Labs has experienced a significant decline in net sales and profitability from March 2022 to March 2025, with net sales dropping from 65.32 Cr to 22.61 Cr and operating profit turning negative, resulting in a loss of 5.08 Cr after tax. Total assets and liabilities also decreased during this period, alongside a negative cash flow from operating activities.

Answer:<BR>The historical performance of Decipher Labs shows a significant decline in net sales and profitability over the years, particularly from March 2022 to March 2025.<BR><BR>Breakdown:<BR>Decipher Labs experienced a decrease in net sales from 65.32 Cr in March 2022 to 22.61 Cr in March 2025. This downward trend is reflected in total operating income, which also fell from 65.32 Cr in March 2022 to 22.61 Cr in March 2025. The company's total expenditure, excluding depreciation, peaked at 59.29 Cr in March 2022 but decreased to 29.84 Cr by March 2025. Operating profit (PBDIT) turned negative, going from a profit of 6.03 Cr in March 2022 to a loss of 7.23 Cr in March 2025. Consequently, profit after tax also declined sharply, from 11.38 Cr in March 2022 to a loss of 5.08 Cr in March 2025. The company's total assets decreased from 41.95 Cr in March 2022 to 23.89 Cr in March 2025, while total liabilities also fell from 41.95 Cr to 23.89 Cr in the same period. Cash flow from operating activities showed a negative trend, with a cash outflow of 9.00 Cr in March 2025, compared to a positive inflow of 8.00 Cr in March 2022. Overall, Decipher Labs has faced significant challenges in maintaining sales and profitability over the years.

View full answer

When is the next results date for Decipher Labs Ltd?

10-Feb-2026

The next results date for Decipher Labs Ltd is 12 February 2026.

The next results date for Decipher Labs Ltd is scheduled for 12 February 2026.

View full answer

Are Decipher Labs Ltd latest results good or bad?

13-Feb-2026

Decipher Labs Ltd's latest Q2 FY26 results are concerning, showing a net profit decline of 101.50% year-on-year and a 26.58% drop in revenue, alongside a half-yearly loss of ₹3.41 crores. These metrics indicate significant challenges and a lack of confidence in the company's future prospects.

Decipher Labs Ltd's latest results for Q2 FY26 indicate a troubling financial situation. The company reported a net profit of ₹0.02 crore, which represents a significant decline of 101.50% year-on-year. Revenue also fell sharply, down 26.58% year-on-year to ₹4.31 crores, despite a sequential improvement from the previous quarter.<BR><BR>While there was a slight recovery in operating margins, which improved to 2.78% from deeply negative figures in the prior quarter, this is largely attributed to cost-cutting rather than genuine operational strength. The company's half-yearly performance shows a consolidated loss of ₹3.41 crores, a stark contrast to a profit of ₹0.62 crores in the same period last year.<BR><BR>Overall, the financial metrics reveal a company struggling with sustained revenue erosion and profitability pressures, raising serious concerns about its operational viability. The absence of institutional investment and low promoter holding further reflect a lack of confidence in the company's future prospects. Given these factors, the latest results can be characterized as bad, indicating significant challenges ahead for Decipher Labs.

View full answer

Should I buy, sell or hold Decipher Labs Ltd?

14-Feb-2026

Why is Decipher Labs Ltd falling/rising?

04-Mar-2026

As of 04-Mar, Decipher Labs Ltd's stock price is Rs. 5.81, down 1.86%, and has fallen 22.53% in the past week and 33.52% in the past month. The company has reported consistent operating losses and a 48.54% decline over the last year, contributing to a significant drop in investor confidence and stock value.

As of 04-Mar, Decipher Labs Ltd's stock price is falling, currently at Rs. 5.81, reflecting a decrease of Rs. 0.11 or 1.86%. This decline is part of a broader trend, as the stock has experienced a significant drop of 22.53% over the past week and 33.52% over the past month. The stock has also hit a new 52-week low of Rs. 5.69 today, indicating ongoing weakness.<BR><BR>The company's performance has consistently underperformed against the benchmark, with a staggering 48.54% decline in the last year, while the Sensex has gained 8.39% during the same period. Over the last three years, Decipher Labs has seen a dramatic 70.51% drop in stock value, contrasting sharply with the 32.28% increase in the benchmark.<BR><BR>Several factors contribute to this downward trend. The company has reported operating losses and has declared negative results for the last six consecutive quarters, with net sales and profit after tax both declining by 35.56%. Furthermore, the company's ability to service its debt is weak, as evidenced by a poor EBIT to Interest ratio of -3.17. The stock is also trading below its moving averages across various time frames, indicating a lack of upward momentum.<BR><BR>Investor participation has decreased significantly, with delivery volume dropping by 56.72% compared to the five-day average, suggesting reduced interest in the stock. Overall, the combination of poor financial performance, weak fundamentals, and declining investor confidence has led to the continued fall in Decipher Labs Ltd's stock price.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -3.17
  • The company has been able to generate a Return on Capital Employed (avg) of 5.19% signifying low profitability per unit of total capital (equity and debt)
2

The company has declared Negative results for the last 6 consecutive quarters

3

Risky - Negative EBITDA

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 6 Cr (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

32

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.02

stock-summary
Return on Equity

-42.37%

stock-summary
Price to Book

0.31

Revenue and Profits:
Net Sales:
3 Cr
(Quarterly Results - Dec 2025)
Net Profit:
-1 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-38.19%
0%
-38.19%
6 Months
-42.79%
0%
-42.79%
1 Year
-46.1%
0%
-46.1%
2 Years
-65.37%
0%
-65.37%
3 Years
-68.78%
0%
-68.78%
4 Years
-90.88%
0%
-90.88%
5 Years
-81.91%
0%
-81.91%

Decipher Labs for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

Announcements stock-summary

Shareholder Meeting / Postal Ballot-Scrutinizers Report

12-Feb-2026 | Source : BSE

Scrutinizers Report for the Extra-ordinary General meeting held on 12.02.2026.

Board Meeting Outcome for Outcome For Board Meeting Held On 12.02.2026

12-Feb-2026 | Source : BSE

Outcome of Board Meeting held on Thursday 12th February 2026.

Shareholder Meeting / Postal Ballot-Outcome of EGM

12-Feb-2026 | Source : BSE

Outcome of the Extra-ordinary General Meeting held on 12.02.2026.

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-25.08%
EBIT Growth (5y)
-229.66%
EBIT to Interest (avg)
-3.17
Debt to EBITDA (avg)
1.24
Net Debt to Equity (avg)
-0.02
Sales to Capital Employed (avg)
1.64
Tax Ratio
17.62%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
-16.88%
ROE (avg)
14.54%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
32
Price to Book Value
0.31
EV to EBIT
-0.51
EV to EBITDA
-0.54
EV to Capital Employed
0.29
EV to Sales
0.39
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-58.12%
ROE (Latest)
-42.37%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Ajjarapu Janakiram (16.43%)

Highest Public shareholder

None

Individual Investors Holdings

78.48%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -44.66% vs -30.04% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 8.47% vs -6,000.00% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.21",
          "val2": "5.80",
          "chgp": "-44.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.42",
          "val2": "-0.64",
          "chgp": "34.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.54",
          "val2": "-0.59",
          "chgp": "8.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-13.08%",
          "val2": "-11.03%",
          "chgp": "-2.05%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is -45.60% vs -21.71% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -797.37% vs 86.85% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.24",
          "val2": "13.31",
          "chgp": "-45.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.19",
          "val2": "-0.02",
          "chgp": "-15,850.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.41",
          "val2": "-0.38",
          "chgp": "-797.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-44.06%",
          "val2": "-0.15%",
          "chgp": "-43.91%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -45.32% vs -24.44% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -307.22% vs 66.32% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10.45",
          "val2": "19.11",
          "chgp": "-45.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.61",
          "val2": "-0.66",
          "chgp": "-446.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.95",
          "val2": "-0.97",
          "chgp": "-307.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-34.55%",
          "val2": "-3.45%",
          "chgp": "-31.10%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -36.98% vs -21.26% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -202.38% vs 37.31% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "22.61",
          "val2": "35.88",
          "chgp": "-36.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.23",
          "val2": "-0.96",
          "chgp": "-653.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.22",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.08",
          "val2": "-1.68",
          "chgp": "-202.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-31.98%",
          "val2": "-2.68%",
          "chgp": "-29.30%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
3.21
5.80
-44.66%
Operating Profit (PBDIT) excl Other Income
-0.42
-0.64
34.38%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.54
-0.59
8.47%
Operating Profit Margin (Excl OI)
-13.08%
-11.03%
-2.05%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is -44.66% vs -30.04% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 8.47% vs -6,000.00% in Dec 2024

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
7.24
13.31
-45.60%
Operating Profit (PBDIT) excl Other Income
-3.19
-0.02
-15,850.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.41
-0.38
-797.37%
Operating Profit Margin (Excl OI)
-44.06%
-0.15%
-43.91%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is -45.60% vs -21.71% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is -797.37% vs 86.85% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
10.45
19.11
-45.32%
Operating Profit (PBDIT) excl Other Income
-3.61
-0.66
-446.97%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.95
-0.97
-307.22%
Operating Profit Margin (Excl OI)
-34.55%
-3.45%
-31.10%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is -45.32% vs -24.44% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2025 is -307.22% vs 66.32% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
22.61
35.88
-36.98%
Operating Profit (PBDIT) excl Other Income
-7.23
-0.96
-653.13%
Interest
0.00
0.22
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.08
-1.68
-202.38%
Operating Profit Margin (Excl OI)
-31.98%
-2.68%
-29.30%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is -36.98% vs -21.26% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -202.38% vs 37.31% in Mar 2024

stock-summaryCompany CV
About Decipher Labs Ltd stock-summary
stock-summary
Decipher Labs Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Decipher Labs Ltd. (formerly known as Combat Drugs Ltd) was incorporated as a Private Limited Company in September, 1986 and was converted into a Public Limited Company in Jun.'92. The company was promoted by Suchit Mohan Lal and Ajay Karan.
Company Coordinates stock-summary
Company Details
4th Flr Plot-94 Sagar Society, Banjara Hills Road No 2 Hyderabad Telangana : 500034
stock-summary
Tel:
stock-summary
info@combatdrugs.in
Registrar Details
Venture Capital & Corporate Investments Ltd , 12-10-167,, MIG- 167,, Bharat Nagar Colony, Hyderabad